Company news
Meiragtx Holdings Plc (NASDAQ:MGTX) news
Every Meiragtx Holdings Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and B...
July 7, 2026
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 14, 2026
MEIRAGTX HOLDINGS PLC : COMPANY ANNOUNCEMENT : AMENDMENT NOTICE
April 20, 2026
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiat...
April 16, 2026
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
April 16, 2026
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xeros...
April 14, 2026
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerosto...
March 26, 2026
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
February 3, 2026
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 7, 2025
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 9, 2025
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Ind...
March 13, 2025
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
March 13, 2025
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Am...
February 21, 2025
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaur...
January 22, 2025
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-In...
December 9, 2024
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
November 24, 2024
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
November 13, 2024
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
October 22, 2024
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Dis...
October 15, 2024
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
October 9, 2024
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
August 12, 2024
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
August 12, 2024
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
May 9, 2024
MeiraGTx to Participate in Upcoming Investor Conferences
April 24, 2024
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
April 18, 2024
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
March 14, 2024
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
February 13, 2024
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
December 21, 2023
MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
November 14, 2023
MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities
October 30, 2023
MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
October 24, 2023
MeiraGTx Reports Second Quarter 2023 Financial and Operational Results
August 10, 2023
MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology
August 1, 2023
MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for...
July 19, 2023
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-In...
June 27, 2023
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently ...
June 22, 2023
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 16, 2023
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 11, 2023
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
May 3, 2023
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 21, 2023
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
March 14, 2023
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
December 8, 2022
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovati...
November 10, 2022
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 4, 2022
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustai...
October 1, 2022